BSP Pharmaceuticals S.p.A. is proud to announce Its participation to the 3rd Annual World ADC Asia Summit of Incheon 2024.
This summit is focused on the trailblazing innovation and collaborations in ADC Drug Development in Asia. The event will be bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore this June.
The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. The massive increase in the quantity of new ADC programs from Asian developers has been especially noticeable since 2022, with the number of ADCs in the clinic surpassing those being developed the United States for the fifth year in a row.
Save the Date!!! Next Wednesday, 26th of June, our Giorgio Salciarini – Technical Business Development Senior Manager, Head of Sales – will present its speech: “Our history to serve the Innovators: a step ahead against the Challenges of Bioconjugate” during the Scientific Program Day1, starting from 12:00 AM.
To request a meeting and for any info, You can send an e-mail at Business.Development@Bsppharmaceuticals.com
